This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

20th - 22nd April 2021
★ 100% virtual conference ★Presented in Central European Time (CET)

Alan Chalmers
Director at Pharma International

Profile

Dr Alan A. Chalmers is a pharmacist with over 40 years industrial experience mainly in the field of pharmaceutical regulatory affairs but also in recent years as a Qualified Person.


A graduate of Strathclyde University in Glasgow UK with a B.Sc. in Pharmacy with specilaisation in Pharmaceutical Technology, his Ph.D. at Manchester University UK was in Pharmaceutical Formulation.


Starting 1975-1978 as Pharmaceutical Development Officer and Clinical Trials Pharmacist of Allen & Hanburys (part of the then Glaxo group), he joined Ciba-Geigy in DRA in 1978. Over 20 years were spent with Ciba-Geigy/CIBA/Novartis in all aspects of regulatory affairs including head of a group company DRA in Canada and for many years as Head of Pharma International regulatory affairs.


Since 1998 he has been an independent regulatory consultant and is Director of his own consultancy company Pharma International   based in Switzerland. He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.

For many years member of the Industrial Pharmacy Executive Committee of the Federation International Pharmaceutique (FIP). Organiser of several Asian Regulatory Conferences   for the International Federation of Pharmaceutical Manufacturers Association (IFPMA).


Since 2010 as accredited by Swissmedic, Dr.Chalmers is a Qualified Person supporting several Swiss pharmaceutical companies trading internationally with pharmaceuticals and medical devices.


Publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as former Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech.

Agenda Sessions

  • Clinical Trials for the Chinese Market

    13:20